WO2024165571A3 - Inhibitors of expression and/or function - Google Patents
Inhibitors of expression and/or function Download PDFInfo
- Publication number
- WO2024165571A3 WO2024165571A3 PCT/EP2024/052934 EP2024052934W WO2024165571A3 WO 2024165571 A3 WO2024165571 A3 WO 2024165571A3 EP 2024052934 W EP2024052934 W EP 2024052934W WO 2024165571 A3 WO2024165571 A3 WO 2024165571A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- expression
- function
- disease
- disorder associated
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 4
- 208000016097 disease of metabolism Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000011759 adipose tissue development Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a metabolic disease or disorder, such as a metabolic disease or disorder associated with non-alcoholic fatty liver disease (NAFLD), and/or obesity and/or a disease or disorder associated with adipogenesis.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23155094 | 2023-02-06 | ||
EP23155094.8 | 2023-02-06 | ||
EP23217288.2 | 2023-12-15 | ||
EP23217288 | 2023-12-15 | ||
EP23219939 | 2023-12-22 | ||
EP23219939.8 | 2023-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024165571A2 WO2024165571A2 (en) | 2024-08-15 |
WO2024165571A3 true WO2024165571A3 (en) | 2024-10-10 |
Family
ID=89845100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2024/052934 WO2024165571A2 (en) | 2023-02-06 | 2024-02-06 | Inhibitors of expression and/or function |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024165571A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005786A2 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
WO2011084193A1 (en) * | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
WO2012005898A2 (en) * | 2010-06-15 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof |
KR20150086442A (en) * | 2014-01-17 | 2015-07-28 | 주식회사 바이오인프라 | Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna |
WO2019051402A1 (en) * | 2017-09-11 | 2019-03-14 | Arrowhead Pharmaceuticals, Inc. | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK39892D0 (en) | 1992-03-25 | 1992-03-25 | Bernard Thorens | PEPTIDE |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
CZ300837B6 (en) | 1996-08-30 | 2009-08-26 | Novo Nordisk A/S | GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use |
WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
AU3247799A (en) | 1998-02-27 | 1999-09-15 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
WO1999043341A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
ATE466027T1 (en) | 1998-02-27 | 2010-05-15 | Novo Nordisk As | DERIVATIVES OF GLP-1 ANALOGUE |
KR101241862B1 (en) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | Novel glp-1 derivatives |
AU2004298425A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel GLP-1 analogues linked to albumin-like agents |
WO2005058954A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
AU2005261740A1 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
EP1799711B1 (en) | 2004-10-07 | 2012-06-20 | Novo Nordisk A/S | Protracted exendin-4 compounds |
WO2006037810A2 (en) | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted glp-1 compounds |
TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
KR20070120112A (en) | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | Extended LP-1 Compound |
GB0606212D0 (en) | 2006-03-28 | 2006-05-10 | Karobio Ab | Pharmaceutical compositions |
US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
JP6017754B2 (en) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Glucagon / GLP-1 receptor co-agonist |
US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
ES2672770T3 (en) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivatives of glucagon-like peptide-1 and its pharmaceutical use |
ES2532116T3 (en) | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Peptides derived with A-B-C-D and their therapeutic uses |
GB0724478D0 (en) | 2007-12-14 | 2008-01-30 | Karobio Ab | Pharmaceutical compositions |
PE20100056A1 (en) | 2008-06-17 | 2010-01-26 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGS AS GIP AGONISTS |
CN103641907A (en) | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | Glucagon/glp-1 receptor co-agonists |
WO2010142665A1 (en) | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | GLUCAGON / GLP-I RECEPTOR CO-AGONISTS |
AR081975A1 (en) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | GLUCAGON ANALOGS |
WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
US10100097B2 (en) | 2012-05-03 | 2018-10-16 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
KR20150043505A (en) | 2012-09-07 | 2015-04-22 | 사노피 | Fusion proteins for treating a metabolic syndrome |
KR102138750B1 (en) | 2012-09-17 | 2020-07-29 | 마드리갈 파마슈티칼스, 인크. | Method of synthesizing thyroid hormone analogs and polymorphs thereof |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
TWI617574B (en) | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | Glucagon and glp-1 co-agonists for the treatment of obesity |
PL2934568T3 (en) | 2012-12-21 | 2018-03-30 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
DK3004155T3 (en) | 2013-05-28 | 2022-01-03 | Takeda Pharmaceuticals Co | PEPTIME CONNECTION |
EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
MX369770B (en) | 2013-11-06 | 2019-11-21 | Zealand Pharma As | Glucagon-glp-1-gip triple agonist compounds. |
AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
EP3129041B1 (en) | 2014-04-07 | 2019-06-12 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
JOP20200119A1 (en) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | Gip and glp-1 co-agonist compounds |
CN115181175A (en) | 2016-04-22 | 2022-10-14 | 深圳市图微安创科技开发有限公司 | GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis |
AR110299A1 (en) | 2016-12-02 | 2019-03-13 | Sanofi Sa | CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid |
CN110087671A (en) | 2016-12-22 | 2019-08-02 | 赛诺菲 | FGF21 compound/GLP-1R agonist combinations of activity ratio with optimization |
CN108570109B (en) | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | Dual target fusion proteins comprising an immunoglobulin Fc portion |
EP3664833B1 (en) | 2017-08-09 | 2023-05-31 | Sanofi | Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis |
JP2020535138A (en) | 2017-09-25 | 2020-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Long-acting coagonists of glucagon and GLP-1 receptors |
CN111465773B (en) | 2017-12-22 | 2021-11-02 | 瓦林格创新股份有限公司 | Panel set, method for assembling the panel set and locking device for furniture products |
EP3775207A1 (en) | 2018-04-05 | 2021-02-17 | Silence Therapeutics GmbH | Sirnas with vinylphosphonate at the 5' end of the antisense strand |
US20210275643A1 (en) | 2018-06-21 | 2021-09-09 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
CA3107345A1 (en) | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Gip/glp1 co-agonist compounds |
MX2022009149A (en) | 2020-01-23 | 2022-12-15 | Lilly Co Eli | Gip/glp1 co-agonist compounds. |
EP4142695A1 (en) | 2020-04-29 | 2023-03-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
TW202216746A (en) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | Long acting glp-1/gip dual agonists |
WO2022002408A1 (en) | 2020-07-02 | 2022-01-06 | Sanofi | Glp-1r agonist / fgf21 fusion proteins |
TW202214679A (en) | 2020-07-22 | 2022-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1 and gip receptor co-agonists |
AU2021361263A1 (en) | 2020-10-17 | 2023-02-16 | Sun Pharmaceutical Industries Limited | GLP-1/GIP dual agonists |
JP2023550594A (en) | 2020-10-30 | 2023-12-04 | ノヴォ ノルディスク アー/エス | GLP-1, GIP, and glucagon receptor triple agonist |
CN115572326B (en) | 2021-06-21 | 2025-01-10 | 广东东阳光药业股份有限公司 | Triple agonist of GLP-1, GCG and GIP receptors |
AU2022320922A1 (en) | 2021-07-30 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Dose regimen for long-acting glp1/glucagon receptor agonists |
-
2024
- 2024-02-06 WO PCT/EP2024/052934 patent/WO2024165571A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011005786A2 (en) * | 2009-07-06 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for enhancing production of a biological product |
WO2011084193A1 (en) * | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
WO2012005898A2 (en) * | 2010-06-15 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof |
KR20150086442A (en) * | 2014-01-17 | 2015-07-28 | 주식회사 바이오인프라 | Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna |
WO2019051402A1 (en) * | 2017-09-11 | 2019-03-14 | Arrowhead Pharmaceuticals, Inc. | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
Non-Patent Citations (9)
Title |
---|
ANONYMOUS: "Material Safety Data Sheet: Adenine Nucleotide Translocator 2 Antibody BIOTIN", 21 April 2021 (2021-04-21), XP093159712, Retrieved from the Internet <URL:https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FBID%2FSDS%2FANT2-BIOTIN%20MSDS.pdf> * |
JANINA-MIRIAM NOY: "Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti-Cancer Efficiency", BIOCONJUGATE CHEMISTRY, vol. 29, no. 2, 18 January 2018 (2018-01-18), US, pages 546 - 558, XP093160098, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00032 * |
JANITH A. SENEVIRATNE: "Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma", INTERNATIONAL JOURNAL OF CANCER, vol. 152, no. 7, 8 November 2022 (2022-11-08), US, pages 1399 - 1413, XP093159664, ISSN: 0020-7136, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ijc.34349> DOI: 10.1002/ijc.34349 * |
JONG BAE SEO: "Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity", NATURE METABOLISM, vol. 1, no. 1, 19 November 2018 (2018-11-19), pages 86 - 97, XP093159888, ISSN: 2522-5812, Retrieved from the Internet <URL:https://www.nature.com/articles/s42255-018-0003-x.pdf> DOI: 10.1038/s42255-018-0003-x * |
JOONSEOK CHO: "Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance", NATURE COMMUNICATIONS, vol. 8, no. 1, 16 February 2017 (2017-02-16), UK, XP093159877, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/ncomms14477> DOI: 10.1038/ncomms14477 * |
LE BRAS MORGANE ET AL: "Chemosensitization by knockdown of adenine nucleotide translocase-2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 66, no. 18, 15 September 2006 (2006-09-15), pages 9143 - 9152, XP002603476, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-4407 * |
LI MING-HSIN ET AL: "Ligand Characteristics Important to Avidity Interactions of Multivalent Nanoparticles", BIOCONJUGATE CHEMISTRY, vol. 28, no. 6, 11 April 2017 (2017-04-11), US, pages 1649 - 1657, XP055917014, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00098 * |
SHENGLONG ZHU: "Slc25a5 regulates adipogenesis by modulating ERK signaling in OP9 cells", CELLULAR & MOLECULAR BIOLOGY LETTERS, vol. 27, no. 1, 2 February 2022 (2022-02-02), PL, XP093159660, ISSN: 1425-8153, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s11658-022-00314-y/fulltext.html> DOI: 10.1186/s11658-022-00314-y * |
TAKAHIRO IKEDA: "Genistein regulates adipogenesis by blocking the function of adenine nucleotide translocase-2 in the mitochondria", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 86, no. 2, 29 November 2021 (2021-11-29), GB, pages 260 - 272, XP093159878, ISSN: 1347-6947, Retrieved from the Internet <URL:https://academic.oup.com/bbb/article-pdf/86/2/260/42565332/zbab203.pdf> DOI: 10.1093/bbb/zbab203 * |
Also Published As
Publication number | Publication date |
---|---|
WO2024165571A2 (en) | 2024-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009563A (en) | Pharmaceutical combination comprising tno155 and ribociclib. | |
SA521422068B1 (en) | GLP-1R Agonists and Uses Thereof | |
CR20210562A (en) | Glp-1r agonists and uses thereof | |
MY156316A (en) | Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products | |
CL2017001983A1 (en) | Pharmaceutical compositions for combination therapy. | |
WO2022109398A9 (en) | Oligonucleotides for dgat2 modulation | |
CO2021001472A2 (en) | Transglutaminase 2 (tg2) inhibitors | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
MX2021010350A (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising leuconostoc citreum wikim0104. | |
AU2018246796A1 (en) | S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis | |
AU2018280875A1 (en) | Solid compositions for oral administration | |
WO2021247885A3 (en) | Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof | |
HK1074592A1 (en) | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP2502996A3 (en) | Anti-FGF23 antibody and pharmaceutical composition comprising the same | |
WO2020247701A3 (en) | Inhibitors of sarm1 | |
MY177974A (en) | A pharmaceutical composition for prevention of diet induced obesity | |
MX2021010349A (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103. | |
PH12019501295A1 (en) | Nutritional compositions containing butyrate and/or lactoferrin and uses thereof | |
MX2022001973A (en) | Formulations for prevention or reduction of c. difficile infections. | |
WO2021158635A8 (en) | Anti-viral compositions and methods of use | |
NZ775294A (en) | Aerosolised formulation | |
MX2023003089A (en) | Solid dosage forms of bacteria. | |
MY130792A (en) | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
WO2024165571A3 (en) | Inhibitors of expression and/or function | |
AU2020378127A8 (en) | Compounds as CD73 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24703564 Country of ref document: EP Kind code of ref document: A2 |